

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, G01N 33/72</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/60160</b> <b>(43) International Publication Date:</b> 25 November 1999 (25.11.99)
<b>(21) International Application Number:</b> PCT/US99/10344 <b>(22) International Filing Date:</b> 12 May 1999 (12.05.99) <b>(30) Priority Data:</b> 60/086,212 21 May 1998 (21.05.98) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/086,212 (CIP) Filed on 21 May 1998 (21.05.98) <b>(71) Applicant (for all designated States except US):</b> DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YANG, Fei [CN/US]; Apartment 204, 18375 Caminito Cantilena, San Diego, CA 92128 (US). MACINA, Roberto, A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 92128 (US).		<b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US). <b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING LUNG CANCER  <b>(57) Abstract</b>  The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating lung cancer.		

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, AND STAGING LUNG CANCER**

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed assays for detecting, diagnosing, monitoring, staging, and prognosticating cancers, particularly lung cancer.

**BACKGROUND OF THE INVENTION**

Primary lung cancer is divided into three main types including small cell lung cancer, non-small cell lung cancer, and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer which are grouped together based upon similar behavior patterns and response to treatment which is different from small cell lung cancer. The three types of non-small cell lung cancer are squamous cell carcinoma, adenocarcinoma and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma also develops from the cells that line the airways, but it develops from a particular type of cell that produces mucus (phlegm). In large cell lung cancer, the cells appear large and rounded when viewed under a microscope. Mesothelioma is a rare type of cancer which affects the covering of the lung, the pleura. It is often caused by exposure to asbestos.

Secondary lung cancer is cancer that has started somewhere else in the body (for example, the breast or bowel) and spread to the lungs. The choice of treatment depends on where the cancer began. For example, cancer that has spread from the breast should respond to breast cancer treatments and cancer that has spread from the bowel should respond to bowel

- 2 -

cancer treatments. The stage of a cancer provides information regarding how far a cancer has spread. Staging is important because treatment of the cancer is often decided based upon its stage. Staging is different for non-small cell versus small cell cancers of the lung.

Non-small cell cancer is divided into four stages. Stage I is very localized cancer with no cancer in the lymph nodes. In stage II, cancer has spread to the lymph nodes at the top of the affected lung. In stage III, cancer has spread near to where the cancer started. This can be to the chest wall, the covering of the lung (pleura), the middle of the chest (mediastinum) or other lymph nodes. Stage IV cancer has spread to another part of the body.

Small cell lung cancers are divided into two groups. This is because small cell lung cancer often spreads quite early. Even if spreading of the cancer is not visible on scans, it is likely that some cancer cells will have broken away and traveled through the bloodstream or lymph system. Accordingly, it is often preferred to treat small cell lung cancers as if they have spread, whether or not any secondary cancer is seen.

The two stages of small cell lung cancers are limited disease, that is cancer that can only be seen in one lung and in nearby lymph nodes, and extensive disease, that is cancer that has spread outside the lung to the chest or to other parts of the body. Because surgery is not usually used to treat small cell cancer, except in very early cases, the staging is not as important as it is with some other types of cancer. Chemotherapy with or without radiotherapy is usually preferred for treatment of small cell lung cancers. Initial scans and tests are used for comparison with later scans and test to see how well a patient is responding to treatment.

Procedures used for detecting, diagnosing, monitoring, staging and prognosticating lung cancer are of critical importance to the outcome of the patient. For example,

- 3 -

patients diagnosed with early lung cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized lung cancer. New diagnostic methods which are more sensitive and specific for detecting early lung cancer are clearly needed.

Lung cancer patients are also closely monitored following initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease or metastasis. There is clearly a need for a lung cancer marker which is more sensitive and specific in detecting lung cancer recurrence.

Another important step in managing lung cancer is determination of the stage of the disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of lung cancer is preferable over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of lung cancer would be improved by detecting new markers in cells, tissues or bodily fluids which could differentiate between different stages of invasion.

In the present invention, methods are provided for detecting, diagnosing, monitoring, staging and prognosticating lung cancer via six (6) Lung Specific Genes (LSGs). The six LSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5 or 6. In the alternative, what is meant by the six LSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5 or 6 or

- 4 -

levels of the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5 or 6.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### **SUMMARY OF THE INVENTION**

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of lung cancer in a patient which comprises measuring levels of LSG in a sample of cells, tissue or bodily fluid from the patient and comparing the measured levels of LSG with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in the measured LSG levels in the patient versus levels of LSG in the control is associated with lung cancer.

Another object of the present invention is to provide a method of diagnosing metastatic lung cancer in a patient which comprises measuring LSG levels in a sample of cells, tissue, or bodily fluid from the patient and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured LSG levels in the patient versus levels of LSG in the control is associated with a cancer which has metastasized.

Another object of the present invention is to provide a method of staging lung cancer in a patient which comprises identifying a patient having lung cancer, measuring levels of

- 5 -

LSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue or bodily fluid type of a control. An increase in measured LSG levels in the patient versus LSG levels in the control can be associated with a cancer which is progressing while a decrease or equivalent level of LSG measured in the patient versus the control can be associated with a cancer which is regressing or in remission.

Another object of the present invention is to provide a method of monitoring lung cancer in a patient for the onset of metastasis. The method comprises identifying a patient having lung cancer that is not known to have metastasized, periodically measuring levels of LSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured LSG levels versus control LSG levels is associated with a cancer which has metastasized.

Yet another object of the present invention is to provide a method of monitoring the change in stage of lung cancer in a patient which comprises identifying a patient having lung cancer, periodically measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient, and comparing the measured LSG levels with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a control wherein an increase in measured LSG levels versus the control LSG levels is associated with a cancer which is progressing and a decrease in the measured LSG levels versus the control LSG levels is associated with a cancer which is regressing or in remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be

- 6 -

understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of LSG with those of LSG in a normal human control. What is meant by "levels of LSG" as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, or 6. In the alternative, what is meant by "levels of LSG" as used herein, means levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, or 6 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, or 6. Such levels are preferably measured in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of LSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including lung cancer. Any of the six LSGs may be measured alone in the methods of the invention, or all together or any combination of the six.

By "control" it is meant a human patient without cancer and/or non cancerous samples from the patient, also referred to herein as a normal human control; in the methods for diagnosing or monitoring for metastasis, control may also

- 7 -

include samples from a human patient that is determined by reliable methods to have lung cancer which has not metastasized.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as LSG. Other cancer markers, in addition to LSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

#### ***Diagnostic Assays***

The present invention provides methods for diagnosing the presence of lung cancer by analyzing for changes in levels of LSG in cells, tissues or bodily fluids compared with levels of LSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of LSG in the patient versus the normal human control is associated with the presence of lung cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic lung cancer in a patient having lung cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having lung cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of lung cancer, patients are typically diagnosed with lung cancer following traditional detection methods.



- 8 -

In the present invention, determining the presence of LSG level in cells, tissues, or bodily fluid, is particularly useful for discriminating between lung cancer which has not metastasized and lung cancer which has metastasized. Existing techniques have difficulty discriminating between lung cancer which has metastasized and lung cancer which has not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is LSG, and are compared with levels of LSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just LSG in serum, this level is preferably compared with the level of LSG in serum of a normal human patient. An increase in the LSG in the patient versus the normal human control is associated with lung cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

### **Staging**

The invention also provides a method of staging lung cancer in a human patient.

The method comprises identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG. Then, the method compares LSG levels in such cells, tissues, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is.

- 9 -

associated with a cancer which is progressing and a decrease in the levels of LSG is associated with a cancer which is regressing or in remission.

**Monitoring**

Further provided is a method of monitoring lung cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this inventions is a method of monitoring the change in stage of lung cancer in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for LSG; comparing the LSG levels in such cells, tissue, or bodily fluid with levels of LSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in LSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of LSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

**Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as LSG of the present invention, in

- 10 -

a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, in situ hybridization assays, competitive-binding assays, Western Blot analyses and ELISA assays. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to LSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to LSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to LSG is incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time LSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to LSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to LSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to LSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of LSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

- 11 -

A competition assay may be employed wherein antibodies specific to LSG attached to a solid support and labeled LSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of LSG in the sample.

Nucleic acid methods may be used to detect LSG mRNA as a marker for lung cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the LSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the LSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling

- 12 -

of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

#### **EXAMPLES**

The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

#### **Example 1: LSGs**

Searches were carried out and LSGs identified using the following Search Tools as part of the LIFESEQ® database available from Incyte Pharmaceuticals, Palo Alto, CA:

1. Library Comparison (compares one library to one other library) allows the identification of clones expressed in tumor and absent or expressed at a lower level in normal tissue.
2. Subsetting is similar to library comparison but allows the identification of clones expressed in a pool of

- 13 -

libraries and absent or expressed at a lower level in a second pool of libraries.

3. Transcript Imaging lists all of the clones in a single library or a pool of libraries based on abundance. Individual clones can then be examined using Electronic Northern's to determine the tissue sources of their component ESTs.

4. Protein Function: Incyte has identified subsets of ESTs with a potential protein function based on homologies to known proteins. Some examples in this database include Transcription Factors and Proteases. Some lead were identified by searching in this database for clones whose component EST's showed disease specificity.

Electronic subtractions, transcript imaging and protein function searches were used to identify clones, whose component EST's were exclusively or more frequently found in libraries from specific tumors. Individual candidate clones were examined in detail by checking where each EST originated.

**TABLE 1: LSGs**

SEQ ID NO	Clone ID	Gene ID	
1	126758	29997	Library Comparisons
2	2798946	26723	Library Comparisons
3	3107312	242842	Transcript Imaging
4	1472038	51968	Transcript Imaging
5	126263	221807	Transcript Imaging
6	586271	242745	Transcript Imaging

The following example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A

- 14 -

LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

**Example 2: Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene was evaluated for every example in normal and cancer tissue. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

**Comparative Examples**

For comparative examples similar mRNA expression analysis for genes coding for the diagnostic markers PSA (Prostate Specific Antigen) and PLA2 (Phospholipase A2) was performed. PSA is the only cancer screening marker available in clinical laboratories. When the panel of normal pooled tissues was analyzed, PSA was expressed at very high levels in prostate, with a very low expression in breast and testis. After we analyzed more than 55 matching samples from 14 different tissues, the data corroborated the tissue specificity seen with normal tissue samples. We compared PSA expression in cancer and normal adjacent tissue for 12 matching samples of prostate tissue. The relative levels of PSA were higher in 10 cancer samples (83%). Clinical data recently obtained support the utilization of PLA2 as a staging marker for late stages of prostate cancer. Our mRNA expression data showed overexpression of the mRNA in 8 out of the 12 prostate matching samples analyzed (66%). The tissue specificity for PLA2 was not as good as the one described for PSA. In addition to prostate, also small intestine, liver, and pancreas showed high levels of mRNA expression for PLA2.

**Measurement of SEQ ID NO:1; Clone ID 126758; Gene ID 29997 (Lng101)**

The absolute numbers as depicted in Table 2 are relative levels of expression of LSG Lng101 (SEQ ID NO:1) in 12 normal different tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.



- 16 -

**Table 2: Relative levels of Lng101 Expression in Pooled Samples**

<b>Tissue</b>	<b>NORMAL</b>
Brain	0
Heart	1.55
Kidney	0
Liver	0
Lung	72716
Mammary Gland	2
Prostate	0
Small Intestine	0
Spleen	0
Testis	1
Thymus	0
Uterus	0

The relative levels of expression in Table 2 show that mRNA expression of the LSG Lng101 (SEQ ID NO:1) is very high (72716) in lung compared with all the other normal tissues analyzed. Testis, the calibrator, with a relative expression level of 1, heart (1.55), and mammary gland (2) are the only tissues expressing the mRNA for Lng101. These results demonstrated that Lng101 mRNA expression is highly specific for lung.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Lng101 in 44 pairs of matching samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

- 17 -

**Table 3: Relative Levels of Lng101 Expression in Individual Samples**

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
Lng AC82	Adenocarcinoma	Lung 1	17199	92042
Lng 60XL	Adenocarcinoma	Lung 2	4603	49971
Lng AC66	Adenocarcinoma	Lung 3	7358	116907
Lng AC69	Adenocarcinoma	Lung 4	82953	47644
Lng AC11	Adenocarcinoma	Lung 5	37771	496008
Lng AC39	Adenocarcinoma	Lung 6	2487	15771
Lng AC32	Adenocarcinoma	Lung 7	12634	204254
Lng SQ9X	Squamous cell carcinoma	Lung 8	90774	14462
Lng SQ32	Squamous cell carcinoma	Lung 9	6677	677567
Lng SQ80	Squamous cell carcinoma	Lung 10	50711	47151
Lng SQ16	Squamous cell carcinoma	Lung 11	396	41333
Lng SQ79	Squamous cell carcinoma	Lung 12	10261	354395
Lng 47XQ	Squamous cell carcinoma	Lung 13	2513	5293
Lng SQ44	Squamous cell carcinoma	Lung 14	69033	72
Lng 90X	Squamous cell carcinoma	Lung 15	678	14715
Lng LC71	Large cell carcinoma	Lung 16	155332	44762
Lng LC109	Large cell carcinoma	Lung 17	10191	322737
Lng 75XC	Metastatic from bone cancer	Lung 18	222033	165291
Lng MT67	Metastatic from renal cell cancer	Lung 19	189	35982

- 18 -

Lng MT71	Metastatic from melanoma	Lung 20	122	4270
Bld 32XK		Bladder 1	0	0
Bld 46XK		Bladder 2	0	0
Cln AS45		Colon 1	0	0
Cln C9XR		Colon 2	0	0
Cvx KS52		Cervix 1	0	0
Cvx NK23		Cervix 2	0	0
End 28XA		Endometrium 1	0	0
End 12XA		Endometrium 2	0	0
Kid 106XD		Kidney 1	0	0
Kid 107XD		Kidney 2	0	0
Liv 94XA		Liver 1	0	0
Liv 15XA		Liver 2	0	0
Mam 82XI		Mammary 1	0	0
Mam A06X		Mammary 2	0	0
Pan 71XL		Pancreas 1	0	0
Pan 77X		Pancreas 2	0	0
Pro 20XB		Prostate 1	0	0
Pro 12B		Prostate 2	0	0
SmI 21XA		Sm. Int. 1	0	0
SmI H89		Sm. Int. 2	0	0
Sto AC44		Stomach	13	0
Tst 39X		Testis	4315	0
Utr 135XO		Uterus 1	0	0
Utr 141XO		Uterus 2	0	0

0= Negative

- 19 -

In the analysis of matching samples, the higher levels of expression were in lung, showing a high degree of tissue specificity for this tissue. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of LSG Lng101 in 6 lung cancer tissues compared with their respective normal adjacent (lung samples #4, 8, 10, 14, 16, and 18). There was overexpression in the cancer tissue for 30% of the lung matching samples tested (total of 20 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 30% of the lung matching samples tested are demonstrative of LSG Lng101 (SEQ ID NO:1) being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng101 (SEQ ID NO:1) is depicted in SEQ ID NO: 7.

**Measurement of SEQ ID NO:3; Clone ID 3107312; Gene ID 242842 (Lng105)**

The absolute numbers depicted in Table 4 are relative levels of expression of LSG Lng105 (SEQ ID NO:3) in 12 normal different tissues. All the values are compared to normal kidney (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

- 20 -

**Table 4: Relative levels of Lng105 Expression in Pooled Samples**

<b>Tissue</b>	<b>NORMAL</b>
Brain	1
Heart	1.11
Kidney	558
Liver	0
Lung	9248
Mammary Gland	6
Muscle	0
Prostate	0
Small Intestine	87
Testis	50
Thymus	6
Uterus	23

The relative levels of expression in Table 4 show that mRNA expression of LSG Lng105 (SEQ ID NO:3) is more than 16 fold higher in the pool of normal lung (9248) compared with the next higher expressor (558 for kidney). All the other pooled tissues samples analyzed showed a very low level of expression for Lng105 (SEQ ID NO:3). These results demonstrate that mRNA expression of LSG Lng105 (SEQ ID NO:3) is highly specific for lung.

The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 5.

The absolute numbers depicted in Table 5 are relative levels of expression of Lng105 (SEQ ID NO:3) in 61 pairs of matching samples. All the values are compared to normal small intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

- 21 -

**Table 5: Relative Levels of Lng105 Expression in Individual Samples**

<b>Sample ID</b>	<b>Cancer Type</b>	<b>Tissue</b>	<b>Cancer</b>	<b>Matching Normal</b>
Lng AC82	Adenocarcinoma	Lung 1	1278	742
Lng C17X	Adenocarcinoma	Lung 2	1272	1948
Lng 60XL	Adenocarcinoma	Lung 3	4345	2188
Lng AC66	Adenocarcinoma	Lung 4	1531	1558
Lng AC69	Adenocarcinoma	Lung 5	7232	913
Lng AC88	Adenocarcinoma	Lung 6	7724	24749
Lng AC11	Adenocarcinoma	Lung 7	690	21545
Lng AC39	Adenocarcinoma	Lung 8	16904	370
Lng AC90	Adenocarcinoma	Lung 9	14614	34
Lng AC32	Adenocarcinoma	Lung 10	8720	5061
Lng SQ9X	Squamous cell carcinoma	Lung 11	3603	659
Lng SQ45	Squamous cell carcinoma	Lung 12	32998	1333
Lng SQ56	Squamous cell carcinoma	Lung 13	829	15077
Lng SQ14	Squamous cell carcinoma	Lung 14	7	6865
Lng SQ32	Squamous cell carcinoma	Lung 15	976	10227
Lng SQ80	Squamous cell carcinoma	Lung 16	2769	3554
Lng SQ16	Squamous cell carcinoma	Lung 17	198	292
Lng SQ79	Squamous cell carcinoma	Lung 18	1128	7777
Lng C20X	Squamous cell carcinoma	Lung 19	4	20
Lng 47XQ	Squamous cell carcinoma	Lung 20	276	117

- 22 -

Lng SQ44	Squamous cell carcinoma	Lung 21	3126	1
Lng BR94	Squamous cell carcinoma	Lung 22	709	6
Lng 90X	Squamous cell carcinoma	Lung 23	258	590
Lng LC71	Large cell carcinoma	Lung 24	155332	44762
Lng LC109	Large cell carcinoma	Lung 25	34280	33112
Lng 75XC	Metastatic from bone cancer	Lung 26	749	902
Lng MT67	Metastatic from renal cell cancer	Lung 27	70	6985
Lng MT71	Metastatic from melanoma	Lung 28	742	15992
Bld 32XK		Bladder 1	1	0
Bld 46XK		Bladder 2	0	0
Cvx KS52		Cervix 1	4	0
Cvx NK23		Cervix 2	1	0
Cln AS45		Colon 1	0	1
Cln C9XR		Colon 2	2	1
Cln CM67		Colon 3	0	0
End 28XA		Endometrium 1	7	4
End 12XA		Endometrium 2	0	0
Kid 106XD		Kidney 1	0	186
Kid 107XD		Kidney 2	82	458
Kid 109XD		Kidney 3	169	438
Kid 10XD		Kidney 4	21	186
Kid 11XD		Kidney 5	586	110
Liv 94XA		Liver 1	1	0

- 23 -

Liv 15XA		Liver 2	1	0
Mam A06X		Mammary 1	1	0
Mam B011X		Mammary 2	13	0
Mam 12X		Mammary 3	0	0
Mam 59X		Mammary 4	0	0
Ovr 103X		Ovary 1	15	2
Pan 71XL		Pancreas 1	1	0
Pan 77X		Pancreas 2	4	0
Pro 20XB		Prostate 1	1	1
Pro 12B		Prostate 2	8	0
SmI 21XA		Sm. Int. 1	4	0
SmI H89		Sm. Int. 2	1	0
Sto AC44		Stomach 1	0	2
Sto AC99		Stomach 2	6	2
Tst 39X		Testis	28	2
Utr 85XU		Uterus 1	3	2
Utr 135XO		Uterus 2	2	0
Utr 141XO		Uterus 3	2	6

0= Negative

In the analysis of matching samples, the higher levels of expression were in lung showing a high degree of tissue specificity for lung tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 4).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the



- 24 -

normal adjacent). Table 5 shows overexpression of LSG Lng105 (SEQ ID NO:3) in 13 lung cancer tissues compared with their respective normal adjacent (lung samples #1, 3, 5, 8, 9, 10, 11, 12, 20, 21, 22, 24, and 25). There is overexpression in the cancer tissue for 46% of the colon matching samples tested (total of 28 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in almost half of the lung matching samples tested are demonstrative of Lng105 (SEQ ID NO:3) being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng105 (SEQ ID NO:3) is depicted as SEQ ID NO:8.

**Measurement of SEQ ID NO:6; Clone ID 586271; Gene ID 242745 (Lng107)**

The absolute numbers depicted in Table 6 are relative levels of expression of LSG Lng107 (SEQ ID NO:6) in 12 normal different tissues. All the values are compared to normal mammary gland (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 6: Relative levels of Lng107 Expression in Pooled Samples**

<b>Tissue</b>	<b>NORMAL</b>
Bladder	0
Heart	0
Kidney	0
Liver	0
Lung	23
Mammary Gland	1
Muscle	0
Prostate	0
Small Intestine	0
Testis	0
Thymus	0
Uterus	0

- 25 -

The relative levels of expression in Table 6 show that mRNA expression of LSG Lng107 (SEQ ID NO:6) is 23 fold higher in the pool of normal lung (23) compared to the expression level in the calibrator mammary gland (1). All the other tissues analyzed were negative for Lng107 (SEQ ID NO:6). These results demonstrate that Lng107 mRNA expression is highly specific for lung.

The absolute numbers in Table 6 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 7.

The absolute numbers depicted in Table 7 are relative levels of expression of LSG Lng107 (SEQ ID NO:6) in 57 pairs of matching samples. All the values are compared to normal prostate (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

**Table 7: Relative Levels of Lng107 Expression in Individual Samples**

Sample ID	Cancer Type	Tissue	Cancer	Matching Normal
Lng AC82	Adenocarcinoma	Lung 1	6	2
Lng 60XL	Adenocarcinoma	Lung 2	1	4
Lng AC66	Adenocarcinoma	Lung 3	1	0
Lng AC69	Adenocarcinoma	Lung 4	117	6
Lng AC88	Adenocarcinoma	Lung 5	12	6
Lng AC11	Adenocarcinoma	Lung 6	1	18
Lng AC32	Adenocarcinoma	Lung 7	4	2
Lng AC39	Adenocarcinoma	Lung 8	2	1
Lng AC90	Adenocarcinoma	Lung 9	1	0
Lng SQ9X	Squamous cell	Lung 10	7	0

- 26 -

Lng SQ45	Squamous cell carcinoma	Lung 11	45	1
Lng SQ56	Squamous cell carcinoma	Lung 12	1	23
Lng SQ16	Squamous cell carcinoma	Lung 13	0	0
Lng SQ32	Squamous cell carcinoma	Lung 14	9	5
Lng SQ80	Squamous cell carcinoma	Lung 15	2	0
Lng SQ79	Squamous cell carcinoma	Lung 16	5	11
Lng C20X	Squamous cell carcinoma	Lung 17	0	0
Lng 47XQ	Squamous cell carcinoma	Lung 18	1	0
Lng SQ44	Squamous cell carcinoma	Lung 19	1	0
Lng BR94	Squamous cell carcinoma	Lung 20	1	0
Lng 90X	Squamous cell carcinoma	Lung 21	0	13
Lng LC71	Large cell carcinoma	Lung 22	31	12
Lng LC109	Large cell carcinoma	Lung 23	1	83
Lng 75XC	Metastatic from bone cancer	Lung 24	2	4
Lng MT67	Metastatic from renal cell cancer	Lung 25	0	1
Lng MT71	Metastatic from melanoma	Lung 26	0	24
Bld 32XK		Bladder 1	0	0
Bld 46XK		Bladder 2	0	0
Cln AS45		Colon 1	0	0
Cln C9XR		Colon 2	0	0

- 27 -

Cvx KS52		Cervix 1	0	0
Cvx NK23		Cervix 2	0	0
End 28XA		Endometrium 1	7	0
End 12XA		Endometrium 2	0	0
End 68X		Endometrium 3	3	2
End 8XA		Endometrium 4	0	0
Kid 106XD		Kidney 1	0	0
Kid 107XD		Kidney 2	0	0
Liv 94XA		Liver 1	0	0
Liv 15XA		Liver 2	0	0
Mam A06X		Mammary 1	0	0
Mam B011X		Mammary 2	116	0
Mam 47XP		Mammary 3	0	0
Mam 59X		Mammary 4	1	0
Ovr 103X		Ovary 1	0	0
Pan 71XL		Pancreas 1	0	0
Pan 77X		Pancreas 2	0	0
Pro 20XB		Prostate 1	0	0
Pro 12B		Prostate 2	0	0
SmI 21XA		Sm. Int. 1	0	0
SmI H89		Sm. Int. 2	0	0
Sto AC44		Stomach 1	0	0
Sto MT54		Stomach 2	0	0
Sto TA73		Stomach 3	1	1
Tst 39X		Testis	0	0
Utr 135XO		Uterus 1	0	0
Utr 141XO		Uterus 2	0	0

- 28 -

0= Negative

In the analysis of matching samples, the higher level of expression was in lung, showing a high degree of tissue specificity for this tissue. These results confirm the tissue specificity results obtained with normal pooled samples (Table 6).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 7 shows overexpression of LSG Lng107 (SEQ ID NO:6) in 15 lung cancer tissues compared with their respective normal adjacent (lung samples #1, 3, 4, 5, 7, 8, 9, 10, 11, 14, 15, 18, 19, 20, and 22). There is overexpression in the cancer tissue for 57% of the lung matching samples tested (total of 26 lung matching samples).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in more than half of the lung matching samples tested are demonstrative of Lng107 being a diagnostic marker for lung cancer. The amino acid sequence encoded by Lng107 is depicted in SEQ ID NO:9.

- 29 -

**What is Claimed is:**

1. A method for diagnosing the presence of lung cancer in a patient comprising:
  - (a) measuring levels of LSG in a sample of cells, tissue or bodily fluid obtained from the patient; and
  - (b) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue or bodily fluid obtained from a control, wherein an increase in measured levels of LSG in the patient versus the LSG levels in the control is associated with the presence of lung cancer.
  
2. A method of diagnosing metastatic lung cancer in a patient comprising:
  - (a) measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and
  - (b) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in measured LSG levels in the patient versus the LSG levels in the control is associated with a cancer which has metastasized.
  
3. A method of staging lung cancer in a patient comprising:
  - (a) identifying a patient suffering from lung cancer;
  - (b) measuring levels of LSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and
  - (c) comparing the measured levels of LSG with levels of LSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is progressing and a decrease in the measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is regressing or in remission.

- 30 -

4. A method of monitoring lung cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having lung cancer that is not known to have metastasized;

(b) periodically measuring LSG levels in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the periodically measured levels of LSG with levels of LSG in cells, tissue, or bodily fluid obtained from a control, wherein an increase in any one of the periodically measured levels of LSG in the patient versus the levels of LSG in the control is associated with a cancer which has metastasized.

5. A method of monitoring changes in a stage of lung cancer in a patient comprising:

(a) identifying a patient having lung cancer;

(b) periodically measuring levels of LSG in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of LSG with levels of LSG in a sample of the same cells, tissue, or bodily fluid of a control, wherein an increase in any one of the periodically measured levels of LSG versus levels of LSG in the control is associated with a cancer which is progressing in stage and a decrease in any one of the periodically measured levels of LSG versus the levels of LSG in the control is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4, or 5 wherein the LSG comprises SEQ ID NO: 1, 3 or 6.

## SEQUENCE LISTING

<110> Yang, Fei  
 Macina, Roberto A.  
 Sun, Yongming

<120> A Novel Method of Diagnosing, Monitoring and Staging  
 Lung Cancer

<130> DEX-0036

<140>

<141>

<150> 60/086,212

<151> 1998-05-21

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 507

<212> DNA

<213> Homo sapiens

<400> 1

```

ggcaagtgga accactggct tgggtggattt tgctagattt ttctgatttt taaactcctg 60
aaaaatatcc cagataactg tcatgaagct ggtaactatc ttctgctggt tgaccatcag 120
cctttgtagt tactctgcta ctgccttcct catcaacaaa gtgccccttc ctgttgacaa 180
gttggcacct ttacctctgg acaacattct tccctttatg gatccattaa agcttcttct 240
gaaaactctg ggcatttctg ttgagcacct tgtggagggg ctaaggaagt gtgtaaatga 300
gctgggacca gaggttctg aagctgtgaa gaaactgctg gaggcgctat cacacttggg 360
gtgacatcaa gataaagagc ggaggtggat ggggatggaa gatgatgctc ctatcctccc 420
tgctgaaac ctgttctacc aattatagat caaatgccct aaaatgtagt gaccctgtaa 480
aaggacaaat aaagcaatga atacatt                                     507

```

<210> 2

<211> 1680

<212> DNA

<213> Homo sapiens

<400> 2

```

ggtgtgcagg atataaggtt ggacttccag acccactgcc cgggagagga grggagcggg 60
ccgaggactc cagcgtgccc aggtctggca tcctgcactt gctgccctct gacacctggg 120
aagatggccg gcccgaggac cttcaccctt ctctgtgggt tgctggcagc caccttgatc 180
caagccaccc tcagtccac tgagttctc atcctcggcc caaaagtcac caaagaaaag 240
ctgacacagg agctgaagga ccacaacgcc accagcatcc tgcagcagct gccgctgctc 300

```



```

agtgccatgc gggaaaagcc agccggagga tccctgtgct gggcagcctg gtgaacaccg 360
tcctgaagca catcatctgg ctgaaggcca tcacagctaa catcctccag ctgcagggtga 420
agccctcggc caatgaccag gagctgctag tcaagatccc cctggacatg gtggctggat 480
tcaacacgcc cctggtcaag accatcgtgg agttccacat gacgactgag gccaagcca 540
ccatccgcat ggacaccagt gcaagtggcc ccacccgcct ggtcctcagt gactgtgcca 600
ccagccatgg gagcctgcgc atccaactgc tgcataagct ctccctcctg gtgaacgcct 660
tagctaagca ggtcatgaac ctccctagtgc catccctgcc caatctagtg aaaaaccagc 720
tgtgtcccgat gatcgaggct tccttcaatg gcatgtatgc agacctcctg cagctgggtga 780
aggtgcccac ttccctcagc attgaccgtc tggagtttga ccttctgtat cctgccatca 840
agggtgacac cattcagctc tacctggggg ccaagttggt ggactcacag ggaaagggtga 900
ccaagtgggt caataactct gcagcttccc tgacaatgcc caccctggac aacatcccgt 960
tcagcctcat cgtgagtcag gacgtgggtga aagctgcagt ggctgctgtg ctctctccag 1020
aagaattcat ggtcctgttg gactctgtgc ttcctgagag tgcccatcgg ctgaagtcaa 1080
gcacgaggct gatcaatgaa aaggctgcag ataagctggg atctaccagc atcgtgaaga 1140
tcctaactca ggacactccc gagtttttta tagaccaagg ccatgccaaag gtggcccaac 1200
tgatcgtgct ggaagtgttt cctccagtg aagccctccg ccctttgttc accctgggca 1260
tcgaagccag ctcggaagct cagttttaca ccaaagggtga ccaacttata ctcaacttga 1320
ataacatcag ctctgatcgg atccagctga tgaactctgg gattggctgg ttccaacctg 1380
atgttctgaa aaacatcctc actgagatca tccactccat cctgctgccg aaccagaatg 1440
gcaaattaag atctggggtc ccagtgtcat tgggtgaaggc cttgggattc gaggcagctg 1500
agtcctcact gaccaaggat gcccttgtgc ttactccagc ctcttctgtg aaaccagct 1560
ctcctgtctc ccagtgaaga cttggatggc agccatcagg gaaggctggg tccagctgg 1620
gagtatgggt gtgagctcta tagaccatcc ctctctgcaa tcaataaaca cttgcctgtg 1680

```

&lt;210&gt; 3

&lt;211&gt; 2060

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

cttgagagct ctcaataact tggatcatgga tgaagccgac cgaatactga atatggattt 60
tgagacagag gttgacaagc ctcgagatcg gaaaacattc ctcttctctg ccaccatgac 120
caagaagggt caaaaacttc agcgagcagc tctgaagaat cctgtgaaat gtgccgtttc 180
ctctaaatac cagacagttg aaaaattaca gcaatattat atttttattc cctctaaatt 240
caaggatacc tacctgggtt atattctaaa tgaattggct ggaaactcct ttatgatatt 300
ctgcagcacc tgtaataata ccagagaaac agctttgcta ctgcgaaatc ttggcttcac 360
tgccatcccc ctccatggac aatgagtc gagtaagcgc ctaggatccc ttaataagtt 420
taaggccaag gcccggtcca ttcttctagc aactgacgtt gccagccgag gtttggacat 480
acctcatgta gatgtggttg tcaactttga cattctacc cattccaagg attacatcca 540
tcgagtaggt cgaacagcta gagctgggag ctccggaaa gctattactt ttgtcacaca 600
gtatgatgtg gaactcttcc agcgcataga aacttaatt gggaagaaac taccagggtt 660
tccaacacag gatgatgagg ttatgatgct gacagaacgc gtcccagcg atgtctccac 720
cacogctgct gcaacccctg ctgctgctgc tgctctgct gaatgtggag ccttcggggg 780
ccacactgat ccgcatccct ctcatcgag tccaacctgg acgcaggacc ctgaacctac 840
tgaggggatg gagagaacca gcagagctcc ccaagttggg ggcccatcc cctggggaca 900
agcccatctt cgtacctctc tcgaactaca gggatgtgca gtattttggg gaaattgggc 960
tggaacgcc tcacaaaac ttactgttg cctttgacac tggtcctcc aatctctggg 1020
tcccgctccag gagatgccac ttcttcagtg tgccctgctg gttacaccac cgatttgatc 1080

```

```

ccaaagcctc tagctccttc caggccaatg ggaccaagtt tgccattcaa tatggaactg 1140
ggcgggtaga tggaaatcctg agcgaggaca agctgactat tgggtggaatc aagggtgcat 1200
cagtgatattt cggggagggt ctctgggagc ccagcctggt cttcgctttt gcccatthttg 1260
atgggatattt gggcctcggg tttcccatc tgtctgtgga aggagttcgg cccccgatgg 1320
atgtactggt ggagcagggg ctattggata agcctgtctt ctccttttac ctcaacaggg 1380
accctgaaga gcctgatgga ggagagctgg tcctgggggg ctcggacccg gcacactaca 1440
tcccacccct caccttcgtg ccagtcacgg tcctgccta ctggcagatc cacatggagc 1500
gtgtgaagggt gggcccaggg ctgactctct gtgccaaggg ctgtgctgcc atcctggata 1560
cgggcacgtc cctcatcaca ggaccactg aggagatccg ggccctgcat gcagccattg 1620
ggggaatccc cttgctggct ggggagtaca tcatcctgtg ctcggaaatc ccaaagctcc 1680
ccgcagtctc cttccttctt ggggggtctt ggtttaacct cacggcccat gattacgtca 1740
tccagactac tcgaaatggc gtccgcctct gcttgcctgg tttccaggcc ctggatgtcc 1800
ctccgcctgc agggcccttc tggatcctcg gtgacgtctt cttggggacg tatgtggccg 1860
tcttcgaccg cggggacatg aagagcagcg cccgggtggg cctggcgcg cgtcgactc 1920
gcgagcgga cctcggtatg ggagagactg cgcaggcgca gttccccggg tgacgccccaa 1980
gtgaagcgca tgcgcagcgg gtggtcgcgg aggtcctgct acccagtaaa aatccactat 2040
ttccattgaa aaaaaaaaaa 2060

```

&lt;210&gt; 4

&lt;211&gt; 315

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

taaactctga ctcagatttt aagaaataac ttttgagaaa tagaacaat gaaatcagtt 60
tctccaccac ttaagtatat ctcttagaga tctacagcct ccttttaggg gacatacaaa 120
gtcagttgtg ttgcctttgt tgagtccac cttatattca agtaggtatg actacaaatt 180
ttgaaaatag attgtcacac aataaactgg agtttatgga aacatcagta gaaggaaata 240
caacattcca tccctttaca gagatcattt acttgcaact caggataatt tgtcatgtgt 300
attatctact tatgc 315

```

&lt;210&gt; 5

&lt;211&gt; 895

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

ctaactctgtt acgtaacagc aagacagcgt cacctcacct gttctcgccc tcaaattggga 60
acgtggcctt gggactaaag catagaccac caggctgagt atcctgacct gagtcatccc 120
cagggatcag gagcctccag cagggaacct tccattatat tcttcaagca acttacagct 180
gcaccgacag ttgcatgaa agttctaatt tcttccctcc tctgttgct gccactaatg 240
ctgatgtcca tgggtctctag cagcctgaat ccaggggtcg ccagaggcca cagggaccga 300
ggccaggctt ctaggagatg gctccaggaa ggcgccaag aatgtgagtg caaagattgg 360
ttcctgagag ccccgagaag aaaattcatg acagtgtctg ggctgcaaaa gaagcagtgc 420
ccctgtgatc atttcaaggg caatgtgaag aaaacaagac accaaaggca ccacagaaag 480
ccaaacaagc attccagagc ctgccagcaa tttctcaaac aatgtcagct aagaagcttt 540
gctctgcctt tgtaggagct ctgagcgccc actcttccaa ttaaacttc tcagccaaga 600
agacagttag cacacctacc agacactctt cttctccac ctcactctcc cactgtacct 660

```

acccctaaat cattccagt ctctcaaaaa gcatgttttt caagatcatt ttgtttgttg 720  
 ctctctctag tgtcttcttc tctcgtcagt cttagcctgt gccctcccct taccagget 780  
 taggcttaat tacctgaaag attccaggaa actgtagctt cctagctagt gtcatttaac 840  
 cttaaagtca atcaggaaa tagcaaacag aagtcaataa atatttttaa atgtc 895

<210> 6

<211> 543

<212> DNA

<213> Homo sapiens

<400> 6

ccggcgctgg aggggcgagg accgggtata agaagcctcg tggccttgcc cgggcagccg 60  
 caggttcccc gcgcgccccg agcccccgcg ccatgaagct cgccgccctc ctggggctct 120  
 gcgtggccct gtccctgcagc tccgctgctg ctttcttagt gggtcggcc aagcctgtgg 180  
 cccagcctgt cgctgcgctg gagtcggcgg cggagggcgg ggccgggacc ctggccaacc 240  
 ccctcggcac cctcaacccg ctgaagctcc tgctgagcag cctgggcac cccgtgaacc 300  
 acctcataga gggctcccag aagtgtgtgg ctgagctggg tccccaggcc gtgggggccc 360  
 tgaaggccct gaaggccctg ctggggggccc tgacagtgtt tggctgagcc gagactggag 420  
 catctacacc tgaggacaag acgctgcccc cccgcgaggg ctgaaaaccc cgccgcgggg 480  
 aggaccgtcc atccccctcc cccggcccct ctcaataaac gtgggtaaga gcaaaaaaaaa 540  
 aaa 543

<210> 7

<211> 93

<212> PRT

<213> Homo sapiens

<400> 7

Met	Lys	Leu	Val	Thr	Ile	Phe	Leu	Leu	Val	Thr	Ile	Ser	Leu	Cys	Ser
1				5					10					15	
Tyr	Ser	Ala	Thr	Ala	Phe	Leu	Ile	Asn	Lys	Val	Pro	Leu	Pro	Val	Asp
			20					25					30		
Lys	Leu	Ala	Pro	Leu	Pro	Leu	Asp	Asn	Ile	Leu	Pro	Phe	Met	Asp	Pro
			35				40					45			
Leu	Lys	Leu	Leu	Leu	Lys	Thr	Leu	Gly	Ile	Ser	Val	Glu	His	Leu	Val
			50			55					60				
Glu	Gly	Leu	Arg	Lys	Cys	Val	Asn	Glu	Leu	Gly	Pro	Glu	Ala	Ser	Glu
			65			70				75				80	
Ala	Val	Lys	Lys	Leu	Leu	Glu	Ala	Leu	Ser	His	Leu	Val			
				85					90						

<210> 8

&lt;211&gt; 420

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

Met Ser Pro Pro Pro Leu Leu Gln Pro Leu Leu Leu Leu Leu Pro Leu  
 1 5 10 15

Leu Asn Val Glu Pro Ser Gly Ala Thr Leu Ile Arg Ile Pro Leu His  
 20 25 30

Arg Val Gln Pro Gly Arg Arg Thr Leu Asn Leu Leu Arg Gly Trp Arg  
 35 40 45

Glu Pro Ala Glu Leu Pro Lys Leu Gly Ala Pro Ser Pro Gly Asp Lys  
 50 55 60

Pro Ile Phe Val Pro Leu Ser Asn Tyr Arg Asp Val Gln Tyr Phe Gly  
 65 70 75 80

Glu Ile Gly Leu Gly Thr Pro Pro Gln Asn Phe Thr Val Ala Phe Asp  
 85 90 95

Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Arg Arg Cys His Phe Phe  
 100 105 110

Ser Val Pro Cys Trp Leu His His Arg Phe Asp Pro Lys Ala Ser Ser  
 115 120 125

Ser Phe Gln Ala Asn Gly Thr Lys Phe Ala Ile Gln Tyr Gly Thr Gly  
 130 135 140

Arg Val Asp Gly Ile Leu Ser Glu Asp Lys Leu Thr Ile Gly Gly Ile  
 145 150 155 160

Lys Gly Ala Ser Val Ile Phe Gly Glu Ala Leu Trp Glu Pro Ser Leu  
 165 170 175

Val Phe Ala Phe Ala His Phe Asp Gly Ile Leu Gly Leu Gly Phe Pro  
 180 185 190

Ile Leu Ser Val Glu Gly Val Arg Pro Pro Met Asp Val Leu Val Glu  
 195 200 205

Gln Gly Leu Leu Asp Lys Pro Val Phe Ser Phe Tyr Leu Asn Arg Asp  
 210 215 220

Pro Glu Glu Pro Asp Gly Gly Glu Leu Val Leu Gly Gly Ser Asp Pro

Met Lys Leu Ala Ala Leu Leu Gly Leu Cys Val Ala Leu Ser Cys Ser  
1 5 10 15

Ser Ala Ala Ala Phe Leu Val Gly Ser Ala Lys Pro Val Ala Gln Pro  
20 25 30

Val Ala Ala Leu Glu Ser Ala Ala Glu Ala Gly Ala Gly Thr Leu Ala  
35 40 45

Asn Pro Leu Gly Thr Leu Asn Pro Leu Lys Leu Leu Leu Ser Ser Leu  
50 55 60

Gly Ile Pro Val Asn His Leu Ile Glu Gly Ser Gln Lys Cys Val Ala  
65 70 75 80

Glu Leu Gly Pro Gln Ala Val Gly Ala Val Lys Ala Leu Lys Ala Leu  
85 90 95

Leu Gly Ala Leu Thr Val Phe Gly  
100

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/10344

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; G01N 33/72

US CL :435/4, 6; 436/64

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 6; 436/64

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS search terms: lung specific gene#

STN search terms: ggcaagtggaacc, ctgagagctctcaaatct, ccggcgtggaggggcgagg

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 98/33926 A1 (ABBOTT LABORATORIES) 06 August 1998(06.08.98), see entire reference.	1-6
X	WO 98/20143 A1 (ABBOTT LABORATORIES) 14 May 1998(14.05.98), see entire reference.	1-6

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 AUGUST 1999

Date of mailing of the international search report

02 SEP 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHEELA J. HUFF

Telephone No. (703) 308-0196